Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.

Suppression of estrogen biosynthesis by aromatase inhibition is an effective approach for the treatment of hormone sensitive breast cancer. Third generation non-steroid aromatase inhibitors have shown important benefits in recent clinical trials with postmenopausal women. In this study we have developed a new ligand-based strategy combining important pharmacophoric and structural features according to the postulated aromatase binding mode, useful for the virtual screening of new potent non-steroid inhibitors. A small subset of promising drug candidates was identified from the large NCI database, and their antiaromatase activity was assessed on an in vitro biochemical assay with aromatase extracted from human term placenta. New potent aromatase inhibitors were discovered to be active in the low nanomolar range, and a common binding mode was proposed. These results confirm the potential of our methodology for a fast in silico high-throughput screening of potent non-steroid aromatase inhibitors.

[1]  R. Hartmann,et al.  Synthesis and In Vitro Evaluation of 3‐(1‐Azolylmethyl)‐1H‐indoles and 3‐(1‐Azolyl‐1‐phenylmethyl)‐1H‐indoles as Inhibitors of P450 arom , 1997, Archiv der Pharmazie.

[2]  A. Hofacre,et al.  Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. , 2001, Journal of molecular biology.

[3]  R. Hartmann,et al.  Three-dimensional model of cytochrome P450 human aromatase , 2005, Journal of enzyme inhibition and medicinal chemistry.

[4]  A. Cavalli,et al.  A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. , 2001, Journal of medicinal chemistry.

[5]  Angelo Carotti,et al.  Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. , 2004, Journal of medicinal chemistry.

[6]  R. Raag,et al.  Inhibitor-induced conformational change in cytochrome P-450CAM. , 1993, Biochemistry.

[7]  Silvia Gobbi,et al.  Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. , 2005, Journal of medicinal chemistry.

[8]  Frank E. Blaney,et al.  Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.

[9]  P. Janssen,et al.  R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis. , 1990, Biochemical pharmacology.

[10]  Thierry Langer,et al.  Pharmacophore Modeling and in Silico Screening for New P450 19 (Aromatase) Inhibitors , 2006, J. Chem. Inf. Model..

[11]  L. Browne,et al.  Novel aromatase inhibitors , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  Stewart B Kirton,et al.  Prediction of binding modes for ligands in the cytochromes P450 and other heme‐containing proteins , 2005, Proteins.

[13]  K. Korzekwa,et al.  Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. , 2001, European journal of biochemistry.

[14]  Angelo Carotti,et al.  Three‐dimensional model of the human aromatase enzyme and density functional parameterization of the iron‐containing protoporphyrin IX for a molecular dynamics study of heme‐cysteinato cytochromes , 2006, Proteins.

[15]  R. Brueggemeier,et al.  Synthesis and characterization of azole isoflavone inhibitors of aromatase. , 2005, Bioorganic & medicinal chemistry.

[16]  A. Cavalli,et al.  Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to non-steroidal aromatase inhibitors. , 2000, Bioorganic & medicinal chemistry.

[17]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[18]  D E McRee,et al.  Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features. , 2000, Journal of inorganic biochemistry.

[19]  A. Cavalli,et al.  Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. , 2006, Journal of medicinal chemistry.

[20]  Sason Shaik,et al.  Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. , 2004, Chemical reviews.

[21]  K. Wähälä,et al.  A three-dimensional model of CYP19 aromatase for structure-based drug design , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[23]  R. Brueggemeier,et al.  Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. , 2004, Journal of medicinal chemistry.

[24]  Slobodan Petar Rendic.  Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[25]  M. Neves,et al.  Biochemical and computational insights into the anti-aromatase activity of natural catechol estrogens , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[27]  L. Maltais,et al.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.

[28]  A. Cavalli,et al.  Looking for selectivity among cytochrome P450s inhibitors. , 2002, Journal of medicinal chemistry.

[29]  A. Cavalli,et al.  Nonsteroidal aromatase inhibitors: Recent advances , 2002, Medicinal research reviews.

[30]  W. Denny,et al.  Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. , 1981, Journal of medicinal chemistry.

[31]  Rebecca C Wade,et al.  Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling? , 2005, EMBO reports.

[32]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[33]  Tudor I. Oprea,et al.  Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors , 1996, J. Comput. Aided Mol. Des..

[34]  M. Waterman,et al.  Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography , 2007, Antimicrobial Agents and Chemotherapy.

[35]  W. Denny,et al.  Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring , 1981 .

[36]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[37]  K. Ryan.  Biological aromatization of steroids. , 1959, The Journal of biological chemistry.

[38]  R. Hartmann,et al.  1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase. , 2000, Journal of medicinal chemistry.

[39]  P. Furet,et al.  Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. , 1993, Journal of medicinal chemistry.

[40]  M. Ichikawa,et al.  Synthesis of Benzoxazoles, Benzothiazoles and Benzimidazoles and Evaluation of Their Antifungal, Insecticidal and Herbicidal Activities , 1982 .

[41]  B. Potter,et al.  Non‐Steroidal Aromatase Inhibitors Based on a Biphenyl Scaffold: Synthesis, in vitro SAR, and Molecular Modelling , 2008, ChemMedChem.

[42]  M. Neves,et al.  Combining Computational and Biochemical Studies for a Rationale on the Anti‐Aromatase Activity of Natural Polyphenols , 2007, ChemMedChem.

[43]  E. A. Thompson,et al.  Studies of human placental aromatase. , 1975, Journal of steroid biochemistry.

[44]  N. Stamm,et al.  Estrogen synthetase inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groups. , 1990, Journal of medicinal chemistry.

[45]  Jaroslaw Polanski,et al.  Modeling Robust QSAR 3: SOM-4D-QSAR with Iterative Variable Elimination IVE-PLS: Application to Steroid, Azo Dye, and Benzoic Acid Series , 2007, J. Chem. Inf. Model..

[46]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.